Want to see JP:2395 full AI Analyst Report?
Top Page
Shin Nippon Biomedical Laboratories, Ltd.
(2395)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥1,567.00
▼(-3.39% Downside)
Action:Reiterated
Date:10/07/26
The score is anchored by mixed financial performance (cooling revenue/margins, higher leverage, and inconsistent free cash flow) offset by strong technical positioning (price above key moving averages with positive MACD) and supportive valuation (low P/E and healthy dividend yield).
Positive Factors
Specialized contract research model
The fee-for-service model addresses recurring outsourcing needs across pharmaceutical and biotechnology development. By supporting preclinical safety and evaluation work required before clinical trials, the company participates in an essential stage of the drug-development process.
Negative Factors
Revenue and margin deterioration
The combination of declining revenue and lower margins signals weaker operating momentum after the stronger 2022–2024 period. If this normalization persists, it could reduce earnings growth, limit operating leverage, and make profitability more dependent on project mix and utilization.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized contract research model
The fee-for-service model addresses recurring outsourcing needs across pharmaceutical and biotechnology development. By supporting preclinical safety and evaluation work required before clinical trials, the company participates in an essential stage of the drug-development process.
Read all positive factors
Shin Nippon Biomedical Laboratories, Ltd. (2395) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥62.70B
Dividend Yield3.32%
Average Volume (3M)204.88K
Price to Earnings (P/E)11.7
Beta (1Y)0.82
Revenue Growth1.72%
EPS Growth6.07%
CountryJP
Employees1,680
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)129.00
Shares Outstanding41,632,400
10 Day Avg. Volume233,710
30 Day Avg. Volume204,880
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)1.37
Price to Sales (P/S)1.81
P/FCF Ratio18.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,387.00Price Target Upside-14.49% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)94.9
Revenue Forecast (FY)¥38.37B
Shin Nippon Biomedical Laboratories, Ltd. Business Overview & Revenue Model
Company Description
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide arr...
How the Company Makes Money
The company primarily makes money by providing fee-for-service contract research services to pharmaceutical, biotechnology, and other life science customers. Its core revenue model is based on customers paying for outsourced research work (typical...
Shin Nippon Biomedical Laboratories, Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
62
Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.92B | 32.52B | 32.41B | 26.45B | 25.09B | 17.75B |
| Gross Profit | 16.81B | 15.83B | 16.57B | 14.28B | 13.05B | 9.69B |
| EBITDA | 7.78B | 6.09B | 8.83B | 8.98B | 9.49B | 9.49B |
| Net Income | 5.37B | 4.57B | 4.92B | 5.53B | 6.06B | 7.13B |
Balance Sheet | ||||||
| Total Assets | 100.21B | 105.06B | 92.42B | 76.30B | 58.31B | 39.38B |
| Cash, Cash Equivalents and Short-Term Investments | 14.33B | 18.54B | 12.03B | 10.61B | 10.53B | 7.00B |
| Total Debt | 37.58B | 41.26B | 34.61B | 26.33B | 18.93B | 9.28B |
| Total Liabilities | 57.94B | 61.57B | 52.33B | 42.14B | 31.95B | 19.66B |
| Stockholders Equity | 41.73B | 43.12B | 40.02B | 34.11B | 26.21B | 19.56B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.15B | -3.82B | -6.50B | -951.70M | 4.34B |
| Operating Cash Flow | 0.00 | 8.33B | 7.04B | 2.11B | 4.00B | 5.95B |
| Investing Cash Flow | 0.00 | -6.79B | -11.69B | -6.91B | -5.93B | -4.27B |
| Financing Cash Flow | 0.00 | 4.51B | 5.91B | 5.32B | 6.27B | -4.91B |
Shin Nippon Biomedical Laboratories, Ltd. Technical Analysis
Positive
1622.00
Price Trends
1384.60
Positive
1300.90
Positive
1378.99
Positive
Market Momentum
40.55
Negative
61.92
Neutral
84.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2395, the sentiment is Positive. The current price of 1622 is above the 20-day moving average (MA) of 1446.25, above the 50-day MA of 1384.60, and above the 200-day MA of 1378.99, indicating a bullish trend. The MACD of 40.55 indicates Negative momentum. The RSI at 61.92 is Neutral, neither overbought nor oversold. The STOCH value of 84.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2395.
Shin Nippon Biomedical Laboratories, Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥143.41B | 18.36 | 6.22% | 3.32% | 3.88% | 26.78% | |
66 Neutral | ¥62.70B | 11.67 | ― | 3.32% | 1.72% | 6.07% | |
57 Neutral | ¥76.06B | 41.05 | ― | 2.51% | 3.92% | -52.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥4.52B | -1.19 | ― | 4.00% | -21.55% | -497.97% |
* Healthcare Sector Average
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,506.00
99.20
7.05%
JP:4694
BML
3,835.00
297.80
8.42%
JP:2183
Linical Co., Ltd.
200.00
-131.75
-39.71%
JP:4549
Eiken Chemical Co., Ltd.
2,307.00
3.99
0.17%
Shin Nippon Biomedical Laboratories, Ltd. Corporate Events
SNBL Corrects Earnings Per Share Figure in Q1 FY2026 Disclosure
Aug 5, 2026
Shin Nippon Biomedical Laboratories has corrected an error in its consolidated financial results release for the three months ended June 30, 2026, specifically in the summary information on page one. The revision concerns the basic earnings per sh...
Shin Nippon Biomedical Laboratories Lifts First-Half Earnings Forecast on Strong CRO Performance
Aug 5, 2026
Shin Nippon Biomedical Laboratories has sharply raised its consolidated earnings forecast for the first half of the fiscal year ending March 31, 2027, citing stronger-than-expected results in its CRO business. Revenue is now projected at ¥17,...
SNBL Sets New Management Structure and Highlights FY3/27 Q1 CRO Strategy
Aug 5, 2026
Shin Nippon Biomedical Laboratories, Ltd. outlined its new management structure and future strategic direction alongside reporting an overview of first quarter results for the fiscal year ending March 31, 2027. The briefing highlighted consolidate...
SNBL Delivers Strong Q1 Earnings and Confirms Dividend Outlook
Aug 5, 2026
Shin Nippon Biomedical Laboratories reported strong results for the quarter ended June 30, 2026, with revenue rising 21.5% year on year to ¥7,868 million and profit attributable to owners of the parent surging to ¥1,064 million. The turn...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.